Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AFSSAPS loses patience with implants firm:

This article was originally published in Clinica

Executive Summary

The French healthcare products safety agency, AFSSAPS, has issued a decision banning the further sale and use of a series of medical implantables manufactured by French company, Proconcept, for orthopaedic surgery. The CE marking certificates had expired on the products in February, a fact drawn to the attention of the agency by Proconcept's notified body, TUV Rheinland Product Safety (Germany). The French national society for certification and registration had also mentioned the expired certificate to the French authorities. Despite a series of warnings, the company has not responded to the French authorities. Therefore, the distribution, export and use of the LIFEC lumbar cage, the CIFEC cervical cage, the SRE/SEO lumbar screw systems and the Canaletto carpian canal protectors are banned for all products that were manufactured between February 16 and June 9 2005, bearing the label reference 0197 TUV Rheinland notified body number.

You may also be interested in...

Will MDR Delays Create Roadblocks For Companion Diagnostics Regulation?

Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed is there a risk of delays to these products being able to demonstrate compliance?

India Rare Disease Policy Proposes Crowdfunding But Patients Feel Let Down

Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.

India’s Hilleman Plans ‘Affordable’ Vaccine Against Group B Strep

India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts